191 related articles for article (PubMed ID: 16213624)
1. "Yes", "No" or "Yes, but"? Multinomial modelling of NICE decision-making.
Dakin HA; Devlin NJ; Odeyemi IA
Health Policy; 2006 Aug; 77(3):352-67. PubMed ID: 16213624
[TBL] [Abstract][Full Text] [Related]
2. Decision making by NICE: examining the influences of evidence, process and context.
Cerri KH; Knapp M; Fernández JL
Health Econ Policy Law; 2014 Apr; 9(2):119-41. PubMed ID: 23688554
[TBL] [Abstract][Full Text] [Related]
3. Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.
Claxton K; Palmer S; Longworth L; Bojke L; Griffin S; McKenna C; Soares M; Spackman E; Youn J
Health Technol Assess; 2012; 16(46):1-323. PubMed ID: 23177626
[TBL] [Abstract][Full Text] [Related]
4. When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.
Longworth L; Youn J; Bojke L; Palmer S; Griffin S; Spackman E; Claxton K
Pharmacoeconomics; 2013 Feb; 31(2):137-49. PubMed ID: 23329429
[TBL] [Abstract][Full Text] [Related]
5. Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis.
Devlin N; Parkin D
Health Econ; 2004 May; 13(5):437-52. PubMed ID: 15127424
[TBL] [Abstract][Full Text] [Related]
6. National Institute for Clinical Excellence (NICE): Is economic appraisal working?
Towse A; Pritchard C
Pharmacoeconomics; 2002; 20 Suppl 3():95-105. PubMed ID: 12457430
[TBL] [Abstract][Full Text] [Related]
7. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
Andronis L; Barton P; Bryan S
Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
[TBL] [Abstract][Full Text] [Related]
8. Differences in cancer drug assessment between Spain and the United Kingdom.
Lozano-Blázquez A; Dickson R; Fraga-Fuentes MD; Martínez-Martínez F; Calleja-Hernández MÁ
Eur J Cancer; 2015 Sep; 51(13):1843-52. PubMed ID: 26119375
[TBL] [Abstract][Full Text] [Related]
9. The Role of Noncomparative Evidence in Health Technology Assessment Decisions.
Griffiths EA; Macaulay R; Vadlamudi NK; Uddin J; Samuels ER
Value Health; 2017 Dec; 20(10):1245-1251. PubMed ID: 29241883
[TBL] [Abstract][Full Text] [Related]
10. Opportunity costs and local health service spending decisions: a qualitative study from Wales.
Karlsberg Schaffer S; Sussex J; Hughes D; Devlin N
BMC Health Serv Res; 2016 Mar; 16():103. PubMed ID: 27012523
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?
Walley T
CNS Drugs; 2004; 18(1):1-12. PubMed ID: 14731055
[TBL] [Abstract][Full Text] [Related]
12. Using health outcomes data to inform decision-making: government agency perspective.
Taylor R
Pharmacoeconomics; 2001; 19 Suppl 2():33-8. PubMed ID: 11700787
[TBL] [Abstract][Full Text] [Related]
13. The role of NICE technology appraisal in NHS rationing.
Walker S; Palmer S; Sculpher M
Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
[TBL] [Abstract][Full Text] [Related]
14. Seeing the NICE side of cost-effectiveness analysis: a qualitative investigation of the use of CEA in NICE technology appraisals.
Bryan S; Williams I; McIver S
Health Econ; 2007 Feb; 16(2):179-93. PubMed ID: 16960851
[TBL] [Abstract][Full Text] [Related]
15. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.
Kaltenthaler E; Boland A; Carroll C; Dickson R; Fitzgerald P; Papaioannou D
Health Technol Assess; 2011 May; 15(22):1-82, iii-iv. PubMed ID: 21561569
[TBL] [Abstract][Full Text] [Related]
16. A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?
Cowles E; Marsden G; Cole A; Devlin N
Appl Health Econ Health Policy; 2017 Aug; 15(4):469-477. PubMed ID: 28130691
[TBL] [Abstract][Full Text] [Related]
17. The Influence of Cost-Effectiveness and Other Factors on Nice Decisions.
Dakin H; Devlin N; Feng Y; Rice N; O'Neill P; Parkin D
Health Econ; 2015 Oct; 24(10):1256-1271. PubMed ID: 25251336
[TBL] [Abstract][Full Text] [Related]
18. An analysis of NICE's 'restricted' (or 'optimized') decisions.
O'Neill P; Devlin NJ
Pharmacoeconomics; 2010; 28(11):987-93. PubMed ID: 20936882
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation and decision making in the UK.
Buxton MJ
Pharmacoeconomics; 2006; 24(11):1133-42. PubMed ID: 17067197
[TBL] [Abstract][Full Text] [Related]
20. National Institute for Clinical Excellence (NICE). HTA rhyme and reason?
Taylor R
Int J Technol Assess Health Care; 2002; 18(2):166-70. PubMed ID: 12053416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
